Pfizer (PFE) – Analysts’ Recent Ratings Updates

A number of research firms have changed their ratings and price targets for Pfizer (NYSE: PFE):

• 4/29/2026 – Pfizer had its price target raised by Citigroup Inc. from $26.00 to $27.00. They now have a “neutral” rating on the stock.
• 4/20/2026 – Pfizer had its “underperform” rating reaffirmed by Royal Bank Of Canada. They now have a $25.00 price target on the stock.
• 4/16/2026 – Pfizer is now covered by CICC Research. They set an “outperform” rating and a $33.00 price target on the stock.
• 4/13/2026 – Pfizer had its price target raised by UBS Group AG from $25.00 to $27.00. They now have a “neutral” rating on the stock.
• 4/10/2026 – Pfizer had its price target raised by Morgan Stanley from $27.00 to $28.00. They now have an “equal weight” rating on the stock.
• 4/9/2026 – Pfizer had its price target lowered by Bank of America Corporation from $27.00 to $26.00. They now have a “neutral” rating on the stock.
• 3/24/2026 – Pfizer had its price target raised by Guggenheim from $35.00 to $36.00. They now have a “buy” rating on the stock.
• 3/17/2026 – Pfizer was given a new $27.00 price target by Morgan Stanley. They now have a “positive” rating on the stock.
• 3/17/2026 – Pfizer had its price target raised by HSBC Holdings plc from $29.00 to $32.00. They now have a “buy” rating on the stock.
• 3/9/2026 – Pfizer had its “outperform” rating reaffirmed by BMO Capital Markets. They now have a $30.00 price target on the stock.

Pfizer Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, June 12th. Investors of record on Friday, May 8th will be issued a dividend of $0.43 per share. The ex-dividend date is Friday, May 8th. This represents a $1.72 dividend on an annualized basis and a yield of 6.5%. Pfizer’s payout ratio is presently 126.47%.

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.